Loading
A phase 3 trial of Pembrolizumab, Oxaliplatin, Bevacizumab and Cetuximab in colorectal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is a phase 3 interventional study registered as NCT05239741 by Merck Sharp & Dohme LLC, with 100 participants enrolled, started 2022-04-02 and due to reach its primary completion in 2028-09-19. Interventions recorded: Pembrolizumab, Oxaliplatin, Leucovorin, 5-fluorouracil, Irinotecan and Bevacizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Bevacizumab, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
Shares Cetuximab, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/